Navigation Links
NanoBio to Announce Key Clinical and Preclinical Data in Nine Presentations at ICAAC/IDSA 2008
Date:10/21/2008

Findings confirm that NanoBio's nanoemulsion technology is effective when

used in therapeutic applications and vaccines

ANN ARBOR, Mich., Oct. 21 /PRNewswire/ -- NanoBio Corporation announced today that it will present compelling new data in nine presentations that detail key milestones in its clinical and preclinical development programs in onychomycosis, herpes labialis, cystic fibrosis and an intra-nasal influenza vaccine during the joint meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Diseases Society of America (IDSA) in Washington, DC, October 25-28.

The company's presentation schedule during the conference is detailed below. NanoBio will also exhibit at corporate booth #408.

Sunday, October 26, 2008

11:15 a.m. - 12:15 p.m. A Novel Nanoemulsion Adjuvant Enhancing the Immune Response to beta-propiolactone Inactivated Influenza Virus Using a Nasal Route in a Ferret Model, Poster #G-1194

Monday, October 27, 2008

11:15 a.m. - 12:15 p.m. Novel Nanoemulsion NB-001 Permeates Skin by the Follicular Route, Poster #A-1898

11:15 a.m. - 12:15 p.m. NB-002, a Novel Nanoemulsion with Anti-Dermatophyte Activity, Poster #M-2134

11:15 a.m. - 12:15 p.m. Mechanism of Skin Penetration and Distribution of a Novel Nanoemulsion, Poster #M-2135

12:15 p.m. - 1:15 p.m. Safety, Tolerability and Pharmacokinetics of NB-001 in a Phase 2 Dose-Ranging Trial in Subjects with Recurrent Herpes Labialis, Presentation #V-3539

12:15 p.m. - 1:15 p.m. NB-001, A Novel Nanoemulsion Active Against Acyclovir (ACV)- and Foscarnet (FOS)-Resistant Herpes Simplex Virus (HSV) 1 and 2, Poster #V-3538

Tuesday, October 28, 2008

9:00 a.m. - 9:15 a.m. Oral Presentation: Subject-Assessed Time to Healing in a Randomized, Double-Blind, Vehicle-Controlled Trial of a Novel Topical Antiviral Nanoemulsion (NB-001) for Recurrent Herpes Labialis

11:15 a.m. - 12:15 p.m. Novel Nanoemulsion Antimicrobials Tested Against Nine Gram-Positive Species, Poster #F1-3944

11:15 a.m. - 12:15 p.m. Antimicrobial Activity of Nanoemulsions Tested Against Seven Gram-Negative Species, Poster #F1-3945

About NanoBio:

NanoBio(R) Corp. is a privately held biopharmaceutical company focused on developing and commercializing anti-infective products and mucosal vaccines derived from its patented NanoStat(TM) technology platform. The company's lead clinical product candidates are treatments for herpes labialis (cold sores), onychomycosis (nail fungus), acne, cystic fibrosis and mucosal vaccines for influenza and hepatitis B. Company headquarters and laboratory facilities are located in Ann Arbor, Mich.


'/>"/>
SOURCE NanoBio Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Daniel B. Dubin, M.D., Joins NanoBio Corp.s Board of Directors
2. FierceBiotech Names NanoBio Corporation as One of the Fierce 15 Biotech Companies of 2008
3. David M. Stout Joins NanoBio Corporations Board of Directors
4. Dr. Joyce Sutcliffe Joins the NanoBio Team as Vice President of Research
5. NanoBio Expands Drug Development Team for Its Anti-Infective Products
6. Cephalon and Eurand Announce Notification of Generic Filing for Cyclobenzaprine Hydrochloride Extended-Release Capsules
7. Advanced Life Sciences Announces Presentations at Fall Scientific and Investor Conferences and Third Quarter 2008 Earnings Conference Call
8. NxStage Announces Streamline(TM) Blood Tubing Set Supply Agreement with Renal Advantage Inc.
9. BioElectronics Announces Significant Progress in Canadian and International Distribution
10. Instrumentation Laboratory Announces Passion & Results Awards Program
11. CV Therapeutics Announces Presentations at American Heart Association Scientific Sessions 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... , March 22, 2017 /PRNewswire/ - FACIT announced ... "Company" or "Propellon"), a start-up created by FACIT ... therapeutics. FACIT,s investment, combined with non-dilutive capital, achieves ... The seed funding enables Propellon to accelerate the ... Company for financing and/or entering a strategic partnership ...
(Date:3/22/2017)... ... ... executive recruitment firm, Slone Partners, is proud to have been named a Top 50 ... Scanlon Media is one of the most respected life science publications in the United ... , “It is a great honor for Slone Partners to be part of this ...
(Date:3/22/2017)... ... March 21, 2017 , ... Benchworks CEO ... Executive Officer Forum on March 23-24 in San Diego. The event is a ... diagnostic industries. , Benchworks Vice President Christian Meyer will also participate in the ...
(Date:3/22/2017)... ... March 21, 2017 , ... ... has unveiled its innovative Quantum peristaltic pump with patented ReNu single-use (SU) ... the new standard for high-pressure feed pumps in SU tangential flow filtration ...
Breaking Biology Technology:
(Date:3/2/2017)... Who risk to be deprived of its ... report: https://www.reportbuyer.com/product/4313699/ WILL APPLE AND SAMSUNG ... Fingerprint sensors using capacitive technology represent a fast growing ... forecasts an increase of 360% of the number of ... fingerprint sensor market between 2014 and 2017 (source : ...
(Date:3/1/2017)... 2017  Aware, Inc. (NASDAQ: AWRE), a leading supplier ... P. Moberg has resigned, effective March 3, 2017, ... Officer and Treasurer of Aware citing a desire to ... member of the Board of Directors of Aware. ... Officer and co-President, General Counsel has been named Chief ...
(Date:2/28/2017)... February 28, 2017 News solutions for biometrics, ... ... from 14 to 16 March, Materna will present its ... how seamless travel is a real benefit for passengers. To ... to their passenger touch point solutions to take passengers through the ...
Breaking Biology News(10 mins):